Ninlaro maintenance therapy extends PFS in posttransplant myeloma

Maintenance therapy with ixazomib significantly extended PFS compared with placebo for certain patients with myeloma, according to the agent’s manufacturer.
Ixazomib (Ninlaro, Takeda), an oral proteasome inhibitor, is approved for use in combination with lenalidomide (Revlimid, Celgene) and dexamethasone for patients with multiple myeloma who received at least one prior treatment. The agent — which is not approved as maintenance therapy for myeloma after autologous stem cell transplant — remains under investigation for a variety of myeloma treatment settings, as well as for